Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy

NCT07606352 is registered in ClinicalTrials.gov with Sitala Bio LTD as lead sponsor.

NCT NCT07606352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07606352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy
Lead sponsor
Sitala Bio LTD
Phase
Phase 2
Overall status
Recruiting
Start date
August 4, 2026
Completion date
September 30, 2027
Enrollment
15 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

igan